Guggenheim Capital LLC Raises Position in Novavax, Inc. (NASDAQ:NVAX)

Guggenheim Capital LLC increased its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 50.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,804 shares of the biopharmaceutical company’s stock after buying an additional 28,977 shares during the quarter. Guggenheim Capital LLC owned 0.10% of Novavax worth $602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in NVAX. ING Groep NV acquired a new stake in shares of Novavax during the first quarter worth $26,000. US Bancorp DE raised its stake in Novavax by 126.1% in the 1st quarter. US Bancorp DE now owns 4,940 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 2,755 shares during the last quarter. Money Concepts Capital Corp acquired a new stake in Novavax during the 4th quarter worth about $37,000. CI Investments Inc. grew its stake in Novavax by 1,572.8% during the 4th quarter. CI Investments Inc. now owns 3,747 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 3,523 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Novavax by 205.3% in the first quarter. Nisa Investment Advisors LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,900 shares during the period. 71.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on NVAX. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Novavax in a research report on Thursday, August 10th. B. Riley raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Wednesday, August 9th. Finally, StockNews.com began coverage on shares of Novavax in a report on Thursday, August 17th. They set a “hold” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $33.00.

Novavax Trading Up 7.6 %

Novavax stock opened at $9.74 on Thursday. The firm has a market cap of $919.49 million, a PE ratio of -1.34 and a beta of 1.69. The stock’s 50 day simple moving average is $8.10 and its two-hundred day simple moving average is $7.79. Novavax, Inc. has a 12 month low of $5.61 and a 12 month high of $33.37.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $1.82. The firm had revenue of $424.40 million for the quarter, compared to analysts’ expectations of $264.16 million. The business’s quarterly revenue was up 128.3% on a year-over-year basis. During the same period last year, the company posted ($6.53) earnings per share. On average, equities research analysts forecast that Novavax, Inc. will post -1.74 EPS for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.